|
1) Oze T, Hiramatsu N, Yakushijin T, et al. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat. 2009; 16: 578-85
|
|
|
|
2) Hiramatsu N, Oze T, Yakushijin T, et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat. 2009; 16: 586-94
|
|
|
|
|
|
3) McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterfeon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360: 1827-38
|
|
|
|
|
|
4) Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360: 1839-50
|
|
|
|
|
|
5) Manns M, et al. 44th Annual Meeting of European Association for the Study of the Liver (EASL) in Copenhagen, 2009
|
|
|
|
|
|
6) Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology. 2008; 48: 398-406
|
|
|
|
|
|
7) Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology. 2009; 49: 1460-8
|
|
|
|
|
|
8) Von Wagner M, Hofmann WP, Teuber G, et al. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology. 2008; 48: 1404-11
|
|
|
|
|
|
9) Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in chronic hepatitis genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology. 2009; 136: 856-62
|
|
|
|
|
|
10) Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008; 135: 1561-7
|
|
|
|
|
|
11) Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology. 2008; 48: 407-17
|
|
|
|
|
|
12) Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed inteferon alfa/ribavirin therapy. Gastroenterology. 2009; 136: 1618-28
|
|
|
|
|
|
13) Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009; 49: 1838-46
|
|
|
|
|
|
14) Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol. 2009; 7: 212-8
|
|
|
|
|
|
15) Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359: 2429-41
|
|
|
|
|
|
16) Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology. 2008; 48: 1033-43
|
|
|
|
|
|
17) Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009; 49: 358-63
|
|
|
|
|
|
18) El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008; 48: 38-47
|
|
|
|
|
|
19) Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009; 44: 952-63
|
|
|
|
|
|
20) Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 205: 7034-9
|
|
|
|
|
|
21) Younossi ZM, Baranova A, Afendy A, et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology. 2009; 49: 763-74
|
|
|
|
|
|
22) Sarasin-Filipowicz M, Krol J, Markiewicz I, et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009; 15: 31-3
|
|
|
|
|
|
23) Welzel TM, Morgan TR, Bonkovsky HL, et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009; 49: 1847-58
|
|
|
|
|
|
24) Su X, Yee LJ, Im K, et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol. 2008; 49: 184-91
|
|
|
|
|
|
25) Morgan TR, Lambrecht RW, Bonkovsky HL, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol. 2008; 49: 548-56
|
|
|
|
|
|
26) Tsukada H, Ochi H, Maekawa T, et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chornic hepatits C. Gastroenterology. 2009; 136: 1796-805
|
|
|
|
|
|
27) Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008; 48: 1753-60
|
|
|
|
|
|
28) Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009; 50: 712-8
|
|
|
|
|
|
29) Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009; 49: 22-31
|
|
|
|
|
|
30) Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009; 136: 496-504
|
|
|
|
|
|
31) Basso M, Giannini EG, Torre F, et al. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological response. Hepatology. 2009; 49: 1442-8
|
|
|
|
|
|
32) Dove LM, Rosen RC, Ramcharran D, et al. Decline in male sexual desire, function and satisfaction curing and after antiviral therapy for chronic hepatitis C. Gastroenterology. 2009; 137: 873-84
|
|
|
|
|
|
33) George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49: 729-38
|
|
|
|
|
|
34) Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135: 821-9
|
|
|
|
|
|
35) Fontana RT, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009; 7: 219-26
|
|
|
|
|
|
36) Arase Y, Suzuki F, Suzuki Y, et al. Substantial virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009; 49: 739-44
|
|
|
|
|